Briefing
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.
In 92 people with metastatic renal cell carcinoma, serial Signatera ctDNA negativity or clearance tracked with longer progression-free survival, and longitudinal positivity during surveillance tracked with shorter progression-free survival.
- Design: Evidence level 2
- Assay: Signatera
JCO Precision OncologyPubMed 39693589DOI 10.1200/PO-24-00667